| Dr Amy Beth Corliss, MD | |
|
3-3420 Kuhio Hwy, Suite B, Lihue, HI 96766-1098 | |
| (808) 245-1100 | |
| Not Available |
| Full Name | Dr Amy Beth Corliss |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 21 Years |
| Location | 3-3420 Kuhio Hwy, Lihue, Hawaii |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194750539 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | MD13786 (Hawaii) | Secondary |
| 208M00000X | Hospitalist | MD13786 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adirondack Medical Center | Saranac lake, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Adirondack Medical Center | 9638081284 | 71 |
News Archive
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.
AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.
When Martie Haselton was a graduate student at the University of Texas, she realized that what she found attractive in a man was changing and that her hormones were playing a role in that change and in finding a potential mate.
Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
› Verified 5 days ago
| Entity Name | Adirondack Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245446533 PECOS PAC ID: 9638081284 Enrollment ID: O20031103000224 |
News Archive
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.
AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.
When Martie Haselton was a graduate student at the University of Texas, she realized that what she found attractive in a man was changing and that her hormones were playing a role in that change and in finding a potential mate.
Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
› Verified 5 days ago
| Entity Name | Adirondack Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1487183174 PECOS PAC ID: 9638081284 Enrollment ID: O20170823002656 |
News Archive
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.
AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.
When Martie Haselton was a graduate student at the University of Texas, she realized that what she found attractive in a man was changing and that her hormones were playing a role in that change and in finding a potential mate.
Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amy Beth Corliss, MD 3-3420 Kuhio Highway, Suite B, Lihue, HI 96766-1098 Ph: (808) 245-1100 | Dr Amy Beth Corliss, MD 3-3420 Kuhio Hwy, Suite B, Lihue, HI 96766-1098 Ph: (808) 245-1100 |
News Archive
Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2010. For the three months ended December 31, 2010, Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $156.0 million, reflecting strong additions of new patients, compared to $110.6 million for the same period in 2009.
AZ-TMJ is once again leading the way in innovative and effective treatments for patients with obstructive sleep apnea (OSA). Approximately one in five adults have at least mild sleep apnea, and one in 15 are classified as moderate sleep apnea sufferers. Sleep apnea is a disorder where a person's ability to breathe is impaired, resulting in a restless sleep and oftentimes snoring.
When Martie Haselton was a graduate student at the University of Texas, she realized that what she found attractive in a man was changing and that her hormones were playing a role in that change and in finding a potential mate.
Dynavax Technologies Corporation announced today data from two studies that differentiate SD-101 from standard-of-care as well as emerging treatments for chronic HCV infection. The findings of a Phase 1b clinical trial and an in vitro study of SD-101's mechanism of action show that the second-generation TLR9 agonist is well tolerated and safe and induces both IFN-lambda and IFN-alpha at concentrations producing antiviral activity. The data will be presented at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Austria in April 2010.
› Verified 5 days ago
Dr. Summer Douban, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3-3420 Kuhio Hwy, Suite B, Lihue, HI 96766 Phone: 808-245-1100 Fax: 808-246-1625 | |
David Adler, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3-3420 Kuhio Hwy Ste B, Lihue, HI 96766 Phone: 808-245-1100 | |
Dr. Katalin J. Terdik, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3-3420 Kuhio Hwy, Suite B, Lihue, HI 96766 Phone: 808-245-1100 |